Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 4:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 130 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infectious Disease of Digestive Tract Clear all
Completed No phase listed Observational

Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa

NCT00027183
View directory record Official record
Conditions
Pseudomonas Infection, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
9 Years to 99 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 30, 2026, 4:00 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)

NCT04501380
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth, Gastrointestinal Disease, Gastrointestinal Infection
Interventions
AEMCOLO (Rifamycin SV MMX)
Drug
Lead sponsor
Bradley Connor
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Sep 30, 2026, 4:00 PM EDT
Not listed No phase listed Observational

Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19

NCT04380870
View directory record Official record
Conditions
Coronavirus Infection
Interventions
Chinese Herbal Medicine
Dietary Supplement
Lead sponsor
Center for Integrated Care
Other
Eligibility
18 Years to 114 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 30, 2026, 4:00 PM EDT
Recruiting Phase 1 Interventional

Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection

NCT07275905
View directory record Official record
Conditions
Cystic Fibrosis (CF), Achromobacter Infection
Interventions
AchromoPhage
Biological
Lead sponsor
Ghady Haidar
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
San Diego, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 30, 2026, 4:00 PM EDT
Completed No phase listed Observational

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

NCT03941184
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 30, 2026, 4:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

NCT04192487
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Healthy Volunteers, HIV/AIDS, HIV Diarrhea, Human Immunodeficiency Virus
Interventions
Crofelemer delayed-release tablets 125mg
Drug
Lead sponsor
Napo Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Tustin, California • Stratford, Connecticut • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Sep 30, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Autologous Fecal Therapy

NCT02046525
View directory record Official record
Conditions
Infectious Disease of Digestive Tract
Interventions
Autologous fecal microbiota therapy, Placebo
Biological · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 30, 2026, 4:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Wells and Enteric Disease Transmission Trial (WET - Trial)

NCT04258059
View directory record Official record
Conditions
Gastrointestinal Infection, Respiratory Viral Infection
Interventions
Active household UV water treatment device, Inactive household UV water treatment device
Device
Lead sponsor
Temple University
Other
Eligibility
6 Months to 59 Months
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 30, 2026, 4:00 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Wells and Enteric Disease Transmission

NCT04826991
View directory record Official record
Conditions
Diarrhea, Gastrointestinal Infection, Respiratory Viral Infection, Waterborne Diseases
Interventions
Active UV Device, Inactive UV Device
Device
Lead sponsor
Temple University
Other
Eligibility
6 Months to 59 Months
Enrollment
908 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 30, 2026, 4:00 PM EDT
Withdrawn No phase listed Observational

An Investigation of the Association Between Helicobacter Pylori Infection and Abdominal Pain in Cystic Fibrosis Patients

NCT00765401
View directory record Official record
Conditions
Cystic Fibrosis, Abdominal Pain, Helicobacter Pylori Infection
Interventions
Not listed
Lead sponsor
Penn State University
Other
Eligibility
5 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Sep 30, 2026, 4:00 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 30, 2026, 4:00 PM EDT
Completed Phase 1Phase 2 Interventional

Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs

NCT00062816
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
ISIS 14803, peginterferon alfa, ribavirin
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Sep 30, 2026, 4:00 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection

NCT04858425
View directory record Official record
Conditions
Covid19
Interventions
Niclosamide, Placebo
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • DeLand, Florida • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 30, 2026, 4:00 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT04806620
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions
Not listed
Lead sponsor
Brain Inflammation Collaborative
Other
Eligibility
2 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Delafield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 30, 2026, 4:00 PM EDT
Completed Not applicable Interventional

Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients

NCT00006617
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Sep 30, 2026, 4:00 PM EDT
Completed Phase 1Phase 2 Interventional

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

NCT06159725
View directory record Official record
Conditions
Persistent Infection, Cystic Fibrosis
Interventions
CMTX-101, Placebo
Drug
Lead sponsor
Clarametyx Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • San Franciso, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 30, 2026, 4:00 PM EDT
Completed Phase 1Phase 2 Interventional

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

NCT06016088
View directory record Official record
Conditions
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Interventions
RSP-1502, Tobramycin inhalation solution
Drug
Lead sponsor
Respirion Pharmaceuticals Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 30, 2026, 4:00 PM EDT
Completed No phase listed Observational

Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerb. in Patients With CF

NCT02109822
View directory record Official record
Conditions
Cystic Fibrosis, Lung Infection, Cystic Fibrosis Pulmonary Exacerbation
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
12 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Birmingham, Alabama • Tucson, Arizona • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 30, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Results available

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT02595866
View directory record Official record
Conditions
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Sep 30, 2026, 4:00 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

NCT01667731
View directory record Official record
Conditions
Hepatitis C, Human Immunodeficiency Virus
Interventions
SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Sep 30, 2026, 4:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Vitamin A and Zinc: Prevention of Pneumonia (VAZPOP) Study

NCT00228254
View directory record Official record
Conditions
Pneumonia, Diarrhea, Acute Upper Respiratory Tract Infections
Interventions
Zinc (12.5 mg/day), vitamin A 10,000 IU per week
Drug
Lead sponsor
Tufts University
Other
Eligibility
6 Months to 36 Months
Enrollment
2,582 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2005 · Synced Sep 30, 2026, 4:00 PM EDT
Completed Phase 2Phase 3 Interventional

Study of Combivir for Patients With Primary Biliary Cirrhosis

NCT00490620
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Combination antiviral therapy, Placebo
Drug
Lead sponsor
University of Alberta
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 1, 2007 · Synced Sep 30, 2026, 4:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Controlled Trial of Social Network Targeting in Honduras

NCT02694679
View directory record Official record
Conditions
Preterm Delivery, Hypothermia, Diarrhea, Upper Respiratory Infection, Omphalitis
Interventions
CBNH
Behavioral
Lead sponsor
Yale University
Other
Eligibility
12 Years and older
Enrollment
31,195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 30, 2026, 4:00 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Gut Microbiota-dependent Health Impacts of Haskap Berries

NCT06546020
View directory record Official record
Conditions
Metabolic Disease, Inflammation, Microbial Colonization
Interventions
Haskap berry smoothie, Placebo comparator
Dietary Supplement
Lead sponsor
Montana State University
Other
Eligibility
35 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 30, 2026, 4:00 PM EDT